Tahmina Rahman - Publications

A phase I study of the OX40 agonist BGB-A445 with or without tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors: dose-escalation results.

Journal: Cancer chemotherapy and pharmacology

Published: March 07, 2025

Characterization of individuals achieving type 2 diabetes remission in real-world settings: bridging clinical evidence and patient experiences.

Journal: Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme

Published: January 14, 2025

Effects of dietary interventions for metabolic acidosis in chronic kidney disease: a systematic review and meta-analysis.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Published: March 18, 2024

Response to: Low-calorie Diets for Remission of Type 2 Diabetes---Do the Benefits Outweigh the Risks?

Journal: Canadian journal of diabetes

Published: July 27, 2023

A Phase 1/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumours.

Journal: British journal of cancer

Published: May 04, 2022

Hemizygous loss of function mutations in CLCN5 causing end-stage kidney disease without Dent disease phenotype.

Journal: Clinical kidney journal

Published: March 28, 2022

Protein over-expression in Escherichia coli triggers adaptation analogous to antimicrobial resistance.

Journal: Microbial cell factories

Published: July 21, 2020

Efflux drug transporters at the forefront of antimicrobial resistance.

Journal: European biophysics journal : EBJ

Published: November 29, 2016